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Abstract 
 
Background: Enoxaparin may be used to prevent central venous catheter-related 
thrombosis in patients with congenital heart disease.  We aimed to determine whether 
current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations 
within prophylactic goal ranges in this patient population.  
Methods:  We implemented a formal protocol aimed at reducing central venous 
catheter-related thrombosis in children with congenital heart disease in January 2016.  
Standard empiric prophylactic enoxaparin dosing regimens were utilized (e.g. less than 
2 months: 0.75 mg/kg/dose every 12 hours; greater than two months: 0.5 mg/kg/dose 
every 12 hours), with anti-factor Xa goal range of 0.25-0.49 IU/mL.  Patients less than 2 
years of age who received enoxaparin and had at least one valid steady-state anti-
factor Xa measurement between 1/25/2016 and 8/31/2016 were retrospectively 
reviewed.   
Results: During the study period, 47 patients had 186 anti-factor Xa concentrations 
measured, of which 20 (11%) were above and 112 (60%) were below prophylactic goal 
range.  Anti-factor Xa concentrations within goal range were ultimately achieved in 31 
patients.  Median dose required to achieve anti-factor Xa concentrations within the 
prophylactic range was 0.89 mg/kg/dose (25%,75%:0.75,1.11) for patients less than 2 
months (n=23 patients) and 0.79 mg/kg/dose (25%,75%:0.62,1.11) for patients greater 
than or equal to 2 months (n=8 patients).  
Conclusions: Enoxaparin doses required to achieve prophylactic anti-factor Xa 
concentrations in young children with congenital heart disease were consistently higher 
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than currently recommended prophylactic dosing regimens.  Further study is needed to 
determine whether dose titration to achieve prophylactic anti-factor Xa concentrations is 
effective in preventing central venous catheter-related thrombosis. 
 
Keywords:  low molecular weight heparin, anticoagulation, congenital cardiac disease, 
prophylaxis, pediatric  
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Introduction 
Neonates, infants and children with congenital heart disease have been shown to have 
a heightened risk of central venous catheter-related thrombotic events.1-6 Prophylactic 
enoxaparin may be used to prevent central venous catheter-associated thrombus 
formation in these patients, but few data exist to guide practitioners on optimal dosing 
strategies in young children.1,4-9  
 
Enoxaparin therapy is monitored using anti-factor Xa assays in children. In the absence 
of renal impairment or other conditions (such as obesity or a hypermetabolic state), anti-
factor Xa concentrations are not routinely monitored in adults. Infants and young 
children, however, require relatively higher enoxaparin doses per kilogram of body 
weight than adults to achieve similar anti-factor Xa concentrations. This variation is 
likely due to differences in volume of distribution, elimination half-life, and renal function 
across the span of childhood development. Furthermore, the undeveloped hemostatic 
system in neonates and infants may also affect enoxaparin dosing requirements.10 A 
small number of studies support the need for higher therapeutic doses of enoxaparin in 
critically ill children,7,11,12 though little data exist on the effectiveness of current 
prophylactic dosing regimens in pediatric population (e.g., children with congenital heart 
disease). 
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We aimed to determine whether standard prophylactic enoxaparin dosing regimens are 
effective in children with congenital heart disease at achieving anti-factor Xa 
concentrations within the goal range of 0.25 – 0.49 IU/mL for thrombus prophylaxis.  
 
Materials and Methods 
A central venous catheter-related thrombus prophylaxis protocol for children with 
congenital heart disease was implemented at our institution in January 2016.  This 
protocol is shown in Figure 1.  Standard prophylactic enoxaparin dosing regimens (e.g. 
< 2 months of age: 0.75 mg/kg/dose subcutaneously every 12 hours; > 2 months of age: 
0.5 mg/kg/dose subcutaneously every 12 hours) were used for all empiric prophylaxis.5 
Doses were titrated by a clinical pharmacist to a target anti-factor Xa range of 0.25 – 
0.49 IU/mL. This goal range was chosen based on local experience in combination with 
literature demonstrating lack of efficacy when targeting a lower prophylactic range (0.1 – 
0.3 IU/mL) in pediatric patients with central venous catheters receiving 
thromboprophylaxis.13,14  Subcutaneous catheters (e.g., Insuflon®) were not used in any 
patients receiving prophylactic enoxaparin therapy. Prior to implementation of this 
protocol, anti-factor Xa levels were not routinely monitored in patients receiving 
prophylactic enoxaparin at our institution. 
 
This retrospective review, which was approved by the Indiana University Institutional 
Review Board, assessed dosing requirements for children treated with prophylactic 
enoxaparin according to this protocol (Figure 1) at Riley Hospital for Children between 
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January 25, 2016 and August 31, 2016. Eligible patients were less than 2 years of age, 
had a diagnosis of congenital heart disease and documentation of at least one 
appropriately drawn (4-6 hours post-enoxaparin dose), steady-state (drawn beyond at 
least the third enoxaparin dose after initiation or after any dosing changes) anti-factor 
Xa concentration. Exclusion criteria included significant renal dysfunction during 
enoxaparin treatment, defined as any form of renal replacement therapy or creatinine 
clearance less than 30 mL/min/1.73m2. Patients were also excluded if they had a 
confirmed diagnosis of heparin-induced thrombocytopenia, platelet count less than 
40,000/mm3, or concurrent therapeutic anticoagulation. Eligible patients were identified 
via a retrospective query of all patients who received enoxaparin during the study 
period.  Data relating to patient demographics, renal function, enoxaparin dosing, and 
anti-factor Xa concentrations were collected from the electronic medical record.  
 
Descriptive statistics were used to characterize the study population, enoxaparin 
dosing, and anti-factor Xa concentrations. Data are provided as median (25%, 75%) or 
absolute counts (%) as appropriate. Creatinine clearance was estimated using the 
bedside Schwartz equation.15   
 
Results 
Forty-seven patients had at least one anti-factor Xa concentration measured during the 
study period. Baseline characteristics of the patient cohort can be found in Table 1.   
Most of our patients were less than 1 year of age, which is representative of the 
cardiovascular surgical patient population at our center (In 2016, 80% of patients who 
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underwent cardiovascular surgery with cardiopulmonary bypass were less than 1 
years). Initial anti-factor Xa concentrations are illustrated in Figure 2. Seventy-one 
percent of the initial anti-factor Xa concentrations were not within the prophylactic goal 
of 0.25 – 0.49 IU/mL, with most falling below the target range.The median initial anti-
factor Xa concentration in this cohort was 0.13 IU/mL (0.06 – 0.19).  Thirty-one patients 
ultimately achieved an anti-factor Xa concentration within the desired prophylactic goal 
range (Table 2). Younger patients were more likely to achieve in-range anti-factor Xa 
concentrations. Furthermore, in-range anti-factor Xa concentrations tended to be 
skewed toward the lower end of the prophylactic goal range and enoxaparin doses 
required to achieve goal concentrations were often higher than traditional prophylactic 
dosing recommendations.  
 
None of the patients in the study cohort experienced major or minor bleeding events 
while on prophylactic enoxaparin according to definitions created by the International 
Society on Thrombosis and Haemostasis.16 
 
Discussion 
Central venous catheter-related thrombotic events are increasingly recognized as 
significant causes of morbidity in children with congenital heart disease, with reported 
rates as high as 25%.1,5-9 Currently, however, there is no clear evidence relating to the 
efficacy of prophylactic anticoagulation in preventing catheter-related thromboses in this 
patient population. The most recent CHEST guidelines published in 2012 and a 
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consensus statement from the American Heart Association currently do not recommend 
enoxaparin for central venous catheter-related thromboprophylaxis.5 Despite the paucity 
of data and absence of formal recommendations, many centers are concerned with the 
risks of central venous catheter-associated thrombosis and utilize prophylactic 
enoxaparin in children with congenital heart disease, traditionally implementing standard 
dosing recommendations.8,9  
 
Diab and colleagues recently evaluated the use of intravenous versus subcutaneous 
enoxaparin therapy in critically ill infants and children.7  While this retrospective 
evaluation was not limited to congenital heart disease patients and included individuals 
who received prophylactic as well as therapeutic enoxaparin, to our knowledge it is the 
only other evaluation to date that assesses the enoxaparin dosing requirements for 
pediatric patients to achieve a specific prophylactic anti-factor Xa goal range. In this 
study, a higher percentage of patients achieved goal range (75%) using traditional 
dosing regimens, though the anti-factor Xa goal range used by the investigators for 
prophylaxis was 0.1 – 0.3 IU/mL, which is slightly lower than our protocolized goal range 
of 0.25 – 0.49 IU/mL.7  Of note, a multicenter, prospective trial published in 2003 
evaluating the efficacy of the low molecular weight heparin, reviparin, in the prevention 
of catheter-related thrombosis also targeted an anti-factor Xa concentration of 0.1 – 0.3 
IU/mL and found no difference in the rate of catheter-related thrombosis in children.13 
Indeed, based on current literature, the prophylaxis target range of 0.1 – 0.3 IU/mL may 
be too low to yield measurable improvements in patient outcomes.13,14 Rather than 
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abandon this medication as a potential effective agent against the challenging problem 
of catheter-related thrombosis, we believe establishing a more aggressive goal range 
for anti-factor Xa concentration and the drug dosage required to attain this range were 
reasonable next steps. 
 
At our institution, we aimed for the prophylactic goal range of 0.25 – 0.49 IU/mL and 
demonstrated that patients under 2 years of age with congenital heart disease required 
consistently higher doses of enoxaparin than are currently recommended to achieve this 
range.  Our experience with prophylactic enoxaparin dosing is consistent with the 
current literature examining therapeutic enoxaparin dosing in this age group. Andrade-
Campos and colleagues found higher therapeutic dosing requirements in a case series 
(n = 14) of pediatric patients in which doses ranged from 1.5 – 2.7 mg/kg/dose every 12 
hours for patients less than 1 year of age.17 Schloemer and colleagues later analyzed 
therapeutic enoxaparin dosing in 192 critically-ill pediatric patients and found that they 
required higher than traditional dosing recommendations to achieve goal therapeutic 
anti-factor Xa concentrations with only 42% achieving goal range on initial dosing (e.g., 
< 2 months of age: 1.5 mg/kg/dose every 12 hours; > 2 months of age: 1 mg/kg/dose 
every 12 hours).11  
 
Importantly, we did not observe any bleeding complications in our cohort, many of 
whom were post-surgical, despite aiming for a slightly more aggressive prophylactic 
goal range than earlier reports.  Based on our results and the absence of any noticeable 
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side effects, we have changed the central venous catheter protocol for children with 
congenital heart disease at our institution to include higher empiric enoxaparin 
prophylaxis dosing for both age groups: 0.9 mg/kg/dose every 12 hours for infants less 
than 2 months of age and 0.75 mg/kg/dose every 12 hours for infants 2 to 12 months of 
age.  We are now focusing our efforts on prospectively determining whether titration of 
enoxaparin therapy toward an anti-factor Xa concentration goal range of 0.25 – 0.49 
IU/mL will result in a decreased occurrence rate of catheter-associated thrombosis and 
ensuring bleeding risk associated with this more aggressive prophylactic dosing of 
enoxaparin is not heightened.   
 
Conclusions 
Enoxaparin doses for patients less than 2 years of age with congenital heart disease 
required to achieve prophylactic anti-factor Xa concentrations between 0.25 – 0.49 
IU/mL were consistently higher than currently recommended pediatric prophylactic 
dosing regimens. Further study is needed to determine whether dose titration to achieve 
anti-Factor Xa concentrations within this goal range is an effective means of preventing 
central venous catheter-related thrombus formation in this patient population. 
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Figure Legends 
Figure 1.  
Central venous catheter thrombosis prophylaxis protocol.  
 
Figure 2.  
Distribution of initial anti-factor Xa concentrations. 
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Table 1.  Patient Characteristics*   
Patients (n) 47 
Age (days) 19.6 (13.5, 143) 
   Neonates (< 30 days) 28 (60%) 
   Infants (30 days – 12 months) 17 (36%) 
   Children (12 – 24 months) 2 (4%) 
Gestational age at birth (weeks) † 38.6 (36.9, 39) 
Female 26 (55%) 
Race‡  
   Caucasian 34 (72%) 
   Black 8 (17%) 
   Hispanic 6 (13%) 
   Asian 2 (4%) 
Weight (kg) 3.3 (2.9, 4.4) 
Cardiac surgery during admission 42 (89%) 
 
* Data represented as median (25%, 75%) or absolute count (%) 
† Gestational age available for 42 of 47 patients in the study (89%) 
‡ Race was self-reported. Respondents could report as many races as they wished. 
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Table 2. Patients Who Achieved Anti-Factor Xa Concentrations within Goal 
Range 
 All Patients 
(n=31) 
Age < 2 Months 
(n=23) 
Age ≥ 2 Months 
(n=8) 
First In-Range 
AFXa (IU/mL) 
0.28 (0.26, 0.4) 0.28 (0.26, 0.38) 0.29 (0.26, 0.42) 
Enoxaparin dose 
required (mg/kg) 
0.87 (0.74, 1.08) 0.88 (0.75, 1.04) 0.79 (0.62, 1.11) 
AFXa: Anti-factor Xa; Data represented as median (25%, 75%) 
 
